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A
 
BSTRACT
Background:
 
Cysteinyl leukotrienes (CysLTs) and
thromboxane (TX) A
 
2
 
 have been implicated in the
pathogenesis of bronchial asthma. Urinary leukotriene
E
 
4
 
 (LTE
 
4
 
) and 11-dehydro-TXB
 
2
 
 (11DTXB
 
2
 
) levels are
often used to assess the production of CysLTs and
TXA
 
2
 
. However, few studies have examined the prod-
ucts of these two mediators in the same asthmatic
patients. To define the potential roles of CysLTs and
TXA
 
2
 
 in the pathogenesis of bronchial asthma in chil-
dren, their urinary levels were measured in the present
study.
 
Methods:
 
Urinary LTE
 
4
 
 and 11DTXB
 
2
 
 levels were
measured by enzyme immunoassay (EIA) and radio-
immunoassay (RIA), respectively. Urine samples from
asthmatic children were measured during the stable
condition and during an acute attack.
 
Results:
 
Urinary LTE
 
4
 
 levels during an acute attack
(median 476 pg/mg creatinine; range 191–1100 pg/
mg creatinine) and during the stable condition
(median 332 pg/mg creatinine; range 128–965 pg/
mg creatinine) were significantly higher (
 
P
 
 < 0.05)
than those of controls (median 233 pg/mg creatinine;
range 103–389 pg/mg creatinine). Urinary 11DTXB
 
2
 
levels during an acute attack and during the stable
condition (median 1666 (range 110–5105) and 1009
(range 46–6070) pg/mg creatinine, respectively) were
significantly higher (
 
P
 
 < 0.05) than those of controls
(median 252 pg/mg creatinine; range 41–716 pg/mg
creatinine). Comparing different stages of asthma,
LTE
 
4
 
 levels during an acute attack were significantly
higher (
 
P
 
 < 0.05) than during the stable condition;
however, there was no difference in urinary TXB
 
2
 
levels.
 
Conclusions:
 
The present findings suggest that high
levels of CysLTs and TXA
 
2
 
 are associated with the
pathogenesis of bronchial asthma. The measurement
of urinary LTE
 
4
 
 and 11DTXB
 
2
 
 would be useful in under-
standing the individual pathogenesis of asthmatic
children.
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2
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4
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2
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I
 
NTRODUCTION
 
Cysteinyl leukotrienes (CysLTs), namely leukotrienes C
 
4
 
,
D
 
4
 
 and E
 
4
 
, and thromboxane (TX) A
 
2
 
 are considered to
play important roles in bronchial asthma.
 
1–10
 
 Cysteinyl
leukotrienes are derived from arachidonic acid by the
action of 5-lipoxygenase and increase vascular perme-
ability, stimulate mucus secretion and induce bronchial
hyperreactiveness and bronchoconstriction. Moreover,
increased production of CysLTs in asthmatic patients
 
in vivo
 
 has been observed in several studies.
 
1–5,11,12
 
A potent bronchoconstrictor, TXA
 
2
 
 is generated from
arachidonic acid by cyclooxygenase. Enhanced TXA
 
2
 
release has also been reported in asthmatic patients
after allergen challenge.
 
7
 
 Owing to the significant roles
of CysLTs and TXA
 
2
 
, their inhibitors or receptor antago-
nists have been developed extensively and recently some
drugs have become available.
 
13
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Although these mediators of asthma have been dis-
cussed previously, few studies have examined the pro-
ducts of these two mediators in the same asthmatic
patients. In addition, few studies have compared the TXA
 
2
 
products of asthmatic patients with those of healthy
control subjects. Leukotriene E
 
4
 
 is a stable product of
CysLTs and is considered an index of the systemic
production of CysLTs production in humans.
 
14
 
 11-
Dehydro-thromboxane B
 
2
 
 (11DTXB
 
2
 
) is the most abun-
dant degradation product of TXB
 
2
 
 and is also considered
an index of systemic TXA
 
2
 
 production.
 
15–17
 
 The measure-
ment of urinary LTE
 
4
 
 and 11DTXB
 
2
 
 is a non-invasive
method for assessing the production of CysLTs and TXA
 
2
 
in vivo
 
, respectively. Oosaki 
 
et al
 
.
 
18
 
 previously estab-
lished sensitive and selective methods of determination of
urinary LTE
 
4
 
 by enzyme immunoassay (EIA) and Ruitta
 
et al
 
.
 
16
 
 established the method of determining urinary
11DTXB
 
2
 
 by radioimmunoassay (RIA). In the present
study, using these methods, the products of CysLTs and
TXA
 
2
 
 were assessed 
 
in vivo
 
 in control subjects and in chil-
dren with bronchial asthma during the stable condition
and during an acute attack.
 
M
 
ETHODS
 
Subjects
 
Twenty-nine children with bronchial asthma (19 males,
10 females) and nine control subjects (six males, three
females) were enrolled in the study (Table 1). The mean
age of asthmatic children and control subjects was
7 years (range 1–15 years) and 8 years (range 1–15
years), respectively. None of the patients had a history of
aspirin sensitivity. Twenty-six of the asthmatic patients
were receiving theophylline, all were using inhaled
disodium cromoglycate (DSCG) and 
 
β
 
2
 
-adrenergic recep-
tor agonists, 10 were receiving inhaled corticosteroids
and 17 were using a leukotriene receptor antagonist
(LTRA). All patients were classified into one of four
categories (intermittent, mild persistent, moderate persist-
ent and severe persistent) according to Glolabal Initiative
for Asthma (GINA) guidelines (http://www/ginasthma.
com/ Table 1). None of the patients had been treated
previously with oral prednisolone (PSL) prior to their
enrollment in the study. In the present study, the urinary
excretion of LTE
 
4
 
 or 11DTXB
 
2
 
 was not influenced by the
usage of LTRA or corticosteroids, because the patients
kept the treatments unmodified throughout the duration of
the study. Informed consent to participate in the study
was obtained from all subjects or their parents.
Urine samples from children with bronchial asthma
were measured during the stable condition and during an
acute attack. Urine samples from nine asthmatic children
selected at random (Table 1, patients 1–9) were also
measured 2 days after treatment. The ‘stable condition’
refers to the condition in which the patients did not com-
plain of any symptoms with or without receiving their
usual medications. The ‘acute attack’ refers to a con-
dition in which the patients complained of some active
symptoms, cough and/or wheezing and/or chest tight-
ness, which were occurring repeatedly on waking and/or
disturbing sleep at night; therefore, they needed addi-
tional treatment to their usual treatments.
 
19
 
 Patients were
treated with steroid and/or theophylline by injection and/
or inhaled 
 
β
 
2
 
-adrenergic receptor agonists and, 2 days
after treatment, they felt better but were still complaining
slightly of some asthmatic symptoms, such as cough and/
or wheezing and/or chest tightness.
Urine samples were collected when the asthmatic
children visited our hospitals during the stable condition
maintaining their usual treatments. Urine samples from
asthmatic children were also collected on arrival at hos-
pital when they had acute asthma attacks. Patients were
treated with theophylline and/or 
 
β
 
2
 
-adrenergic receptor
agonists and/or corticosteroid drip infusion. Urine
samples from nine asthmatic children were collected
2 days after treatment.
 
Measurement of LTE
 
4
 
Urine samples were stored at –80
 
°
 
C and analyzed within
1 month of collection. An aliquot of urine was removed
to determine creatinine concentration. The urinary creat-
inine level was determined using a Creatinine test kit
(Pure Auto S CRE-L; Daiichi-kagaku, Tokyo, Japan).
Approximately 3000 d.p.m. [
 
3
 
H]-LTE
 
4
 
 was added to
each urine sample as an internal standard and the urine
was applied to a Sep-Pak C18 cartridge (Waters, Milford,
MA, USA) that had been preconditioned by the serial
addition of methanol and distilled water. Then, the car-
tridge was washed with distilled water, followed by 40%
methanol; LTE
 
4
 
 was eluted with 80% methanol. This
elution was dried with nitrogen gas and was dissolved
in the elution buffer used in high-performance liquid
chromatography (HPLC; 486 Tunable Absorbance
Detector; Waters) and the solution was injected onto a
C18 reverse-phase column (CAPPCELL PAC UG 120;
Shiseido, Tokyo, Japan). The fractions that contained
peak [
 
3
 
H]-LTE
 
4
 
 radioactivity and also corresponded to the
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retention time of authentic LTE
 
4
 
 were dried and resus-
pended in assay buffer, which was supplied in the Leuko-
triene C4
 
/D4/E4 enzyme-immunoassay system (Amersham,
Buckinghamshire, UK). Urinary LTE4 concentrations deter-
mined by EIA were corrected for recovery of [3H]-LTE4. The
urinary LTE4 level was expressed as pg/mg creatinine.
Measurement of 11DTXB2
The 11DTXB2 was extracted from an acidified sample by
adding an equal volume of octadecylsilyl silica powder
(ODS) suspension (80 mg/mL in 40% ethanol) followed
by mixing, centrifuging (at 2000 g for 3 min at room
temperature) and either decanting or aspirating. The
pellet was washed with an acidic alcohol solution and
then with petroleum ether for deproteinizing and defat-
ting. The 11DTXB2 was eluted by ethyl acetate. The
pooled ethyl acetate was evaporated to dryness with
nitrogen gas. The dried residue, containing 11DTXB2,
was dissolved in the eluent (acetonitril : chloroform :
acetic acid, 10 : 90 : 0.5, v/v/v) and applied to the
open silica mini column (Bond Elute SI; VARIAN, Palo
Alto, CA, USA). The column was washed with the eluent
(acetonitril : chloroform : acetic acid, 20 : 80 : 0.5, v/v/v).
The elution buffer, containing the 11DTXB2, was dried
with nitrogen gas and the amount of 11DTXB2 was
quantitated by RIA (11-Dehydrothromboxane B2 [125I]
RIA kit; Perkin Elmer Life and Analytical Sciences,
Boston, MA, USA). The urinary 11DTXB2 level was also
expressed as pg/mg creatinine.
Statistical analyses
The Mann–Whitney unpaired U-test was used to compare
controls and asthmatic children during the stable condi-
tion and the Wilcoxon paired test was used to compare
asthmatic children during the stable condition and during
an acute attack. Correlation was analyzed by Pearson
correlation analysis. The percentage of changes was
calculated using the following equation: % change =
(level during stable condition – level during attack)
× 100/level during attack. Data are expressed as the
median (range) and P < 0.05 was considered significant.
RESULTS
Urinary LTE4 and 11DTXB2 levels
Urinary levels of LTE4 and 11DTXB2 were measured to
define the potential roles of CysLTs and TXA2 in children
with bronchial asthma.
Leukotriene E4 was measured by EIA. Urinary LTE4
levels are plotted in Fig. 1. Urinary LTE4 levels in
asthmatic children during the stable condition (332
(128–965) pg/mg creatinine) was significantly higher
(P < 0.05) than that of control subjects (233
(103–389) pg/mg creatinine; Fig. 1a). Comparing the
different conditions of asthma, LTE4 levels during an
acute attack (476 (191–1100) pg/mg creatinine) were
significantly higher (P < 0.05) than those during the
stable condition (Fig. 1b).
11-Dehydro-thromboxane B2was measured by RIA
and was detectable in all urine samples. Urinary
11DTXB2 levels are shown in Fig. 2. Urinary 11DTXB2
levels in asthmatic children during the stable condition
(1009 (46–6070) pg/mg creatinine) were significantly
higher (P < 0.05) than those of control subjects (252
(41–716) pg/mg creatinine; Fig. 2a). However, there
was no significant difference in 11DTXB2 levels during an
acute attack (1666 (110–5105) pg/mg creatinine) and
during the stable condition (Fig. 2b).
Urinary levels of LTE4 and 11DTXB2 were observed
during the stable condition, an acute attack and 2 days
after treatment in nine asthmatic children (Fig. 3). Urinary
LTE4 increased from 373 pg/mg creatinine (range
183–556 pg/mg creatinine) during the stable condition
to 546 pg/mg creatinine (range 280–1100 pg/mg
creatinine) during an acute asthma attack and then
decreased to 443 pg/mg creatinine (range 156–872 pg/
mg creatinine) 2 days after treatment (Fig. 3a). In con-
trast, urinary 11DTXB2 levels exhibited different patterns
after an attack. Urinary 11DTXB2 levels increased from
1009 pg/mg creatinine (range 131–2106 pg/mg cre-
atinine) during the stable condition to 1285 pg/mg
creatinine (range 166–3122 pg/mg creatinine) during
an acute asthma attack and gradually decreased to
842 pg/mg creatinine (range 492–2708 pg/mg creati-
nine) 2 days after treatment. However, each patient
showed variable levels of urinary 11DTXB2 2 days after
treatment (Fig. 3b).
Correlations between urinary LTE4 and 
11DTXB2
We assessed the relationship between LTE4 and
11DTXB2 in children with bronchial asthma (Fig. 4). No
relationship was noted between these prostanoids in
children with bronchial asthma or in the controls. In plots
of changes from levels observed during an attack to
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Fig. 1 (a) Urinary leukotriene E4 (LTE4) levels in asthmatic children during the stable condition (median 332 pg/mg creatinine;
range 128–965 pg/mg creatinine) and in controls (median 233 pg/mg creatinine; range 103–389 pg/mg creatinine). (b) Urinary
LTE4 levels in asthmatic children during an acute asthma attack (median 476 pg/mg creatinine; range 191–1100 pg/mg creatinine)
and during the stable condition (median 332 pg/mg creatinine; range 128–965 pg/mg creatinine). Horizontal bars indicate median
values. *P < 0.05.
Fig. 2 (a) Urinary 11-dehydro-thromboxane B2 (11DTXB2) levels in asthmatic children during the stable condition (median
1009 pg/mg creatinine; range 46–6070 pg/mg creatinine) and in controls (median 252 pg/mg creatinine; range 41–716 pg/mg
creatinine). (b) Urinary 11DTXB2 levels in asthmatic children during an acute asthma attack (median 1666 pg/mg creatinine; range
110–5105 pg/mg creatinine) and during the stable condition (median 1009 pg/mg creatinine; range 46–6070 pg/mg creatinine).
Horizontal bars indicate median values. *P < 0.05.
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levels during the stable condition, the changes in LTE4
were not related to changes in 11DTXB2 in children with
bronchial asthma (Fig. 5). Neither gender, age, serum
IgE nor eosinophil count had any relationship with
urinary levels of LTE4 or 11DTXB2 (data not shown). One
patient (no. 5) had high eosinophil counts (1344/µL
during the stable condition; 871/µL during an acute
attack; and 2567/µL when he felt better 2 days after
treatment). However, the eosinophil count did not corre-
late with urinary levels of LTE4 or 11DTXB2. There was no
significant correlation between urinary levels of LTE4 and
the severity of asthma; however, the severity of asthma in
patients with high levels of urinary LTE4 were classified as
‘moderate persistent’ or ‘severe persistent’.
DISCUSSION
Cysteinyl leukotrienes and TXA2 are considered to play
important roles in the pathogenesis of bronchial asthma.
The relationship between urinary LTE4 and 11DTXB2
in the pathogenesis of asthma has been reported by
several investigators;2–5,8,11,13,20 because of the instability
of CysLTs and TXA2, the end-products of the cascade
were determined. However, most studies have been
Fig. 3 Urinary leukotriene E4 (LTE4) and 11-dehydro-thromboxane B2 (11DTXB2) levels in nine children with bronchial asthma
during the stable condition, an acute asthma attack and 2 days after treatment. (a) Urinary LTE4 levels increased from a median
of  373 pg/mg creatinine (range 183–556 pg/mg creatinine) during the stable condition to 546 pg/mg creatinine (range
280–1100 pg/mg creatinine) during an acute asthma attack, decreasing again to 443 pg/mg creatinine (range 156–872 pg/mg
creatinine) 2 days after treatment. (b) Urinary 11DTXB2 levels were apt to increase from a median of 1009 pg/mg creatinine (range
131–2166 pg/mg creatinine) during the stable condition to 1285 pg/mg creatinine (range 166–3122 pg/mg creatinine) during an
acute asthma attack and then decrease slowly to 842 pg/mg creatinine (range 492–2708 pg/mg creatinine) 2 days after treatment.
*P < 0.05.
Fig. 4 Relationship between urinary leukotriene E4 (LTE4) and 11-dehydro-thromboxane B2 (11DTXB2) levels. No relationship was
noted between these prostanoids in (a) control subjects, (b) asthmatic children while in the stable condition and (c) asthmatic children
during an acute asthma attack.
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performed in adults. In the present study, we have
demonstrated the relationship between urinary LTE4 and
11DTXB2 in children with bronchial asthma.
In the present study, urinary LTE4 levels in children with
bronchial asthma during the stable condition were signif-
icantly higher than in control children. In addition, urinary
LTE4 levels in children during an acute asthma attack
were higher than during the stable condition. Asano
et al.5 also demonstrated that patients with mild to mod-
erate asthma excrete LTE4 in the urine at a greater rate
than control subjects. Taylor et al.4 revealed that urinary
LTE4 was significantly higher in asthma patients after
antigen challenge than in control subjects. The results of
the present study are consistent with previous findings in
adult asthmatic patients.3,4,9,11,17,20
In the present study, urinary 11DTXB2 levels were
higher in children with bronchial asthma than in controls.
Unlike LTE4, urinary 11DTXB2 levels did not increase
markedly during an acute attack.
Oosaki et al.3,20 reported on variations in urinary
levels of these mediators in patients with spontaneous
asthma attacks who were monitored for 3 days and
whose state improved. The study of Oosaki et al.3,20
showed that urinary levels of LTE4 were significantly
higher during the attack and returned to control levels
once the patient’s state had improved. In the present
study, the urinary levels of these prostanoids were meas-
ured in asthmatic children during the stable condition,
during an acute attacks and 2 days after treatment. In
eight children, urinary LTE4 levels increased during an
acute attack and decreased 2 days after treatment. One
patient (no. 8) exhibited a different pattern of urinary LTE4
excretion: levels decreased during an acute attack and
then increased when she felt better 2 days after treatment.
However, the urinary 11DTXB2 levels in this patient
increased during an acute attack and then decreased
2 days after treatment. This patient had atopic-type bron-
chial asthma and was treated with theophyline, steroid
inhalant, DSCG and a β2-adrenergic receptor agonist.
Before she was enrolled in the study, she had been
treated with an LTRA for 5 weeks. However, LTRA treat-
ment had little effect on her asthma. Urinary 11DTXB2
levels tended to increase during an asthma attack and
persisted 2 days after treatment. Similar to the findings
of the present study, Oosaki et al. have shown that
the median level of urinary 11DTXB2 was highest during
the 3rd hospital day in atopic-type patients and during the
2nd hospital day in non-atopic-type patients.3
In the present study, urinary levels of LTE4 and
11DTXB2 were slightly higher than those reported previ-
ously.2–5,8,11,13,20 Osamura et al. had reported that urinary
levels of 11DTXB2 were significantly high between 1 and
3 years after birth and that they tended to decrease grad-
ually with age thereafter.21 Because all our subjects were
children (1–15 years of age), this may explain why
the urinary levels of 11DTXB2 were slightly higher in the
present study than those reported previously.
Suzuki et al.2 reported that no significant relationship
was observed between urinary LTE4 and 11DTXB2 in asth-
matic patients. Oosaki et al.3 also examined the relation-
ship in changes (%) between these two metabolites;
however, they noted no significant difference. In the
present study, consistent with results of previous studies,
no relationship was observed between urinary LTE4 and
11DTXB2 in children with bronchial asthma. In addition,
changes (%) in LTE4 levels were not associated with
11DTXB2 levels in children with bronchial asthma. This
suggests that increases in the levels of these two meta-
bolites are not correlated with one another.
Neither gender, age, serum IgE nor eosinophil count
revealed any relationship with urinary levels of LTE4 or
11DTXB2. Eosinophils play an important role in the
Fig. 5 Changes (%) in leukotriene E4 (LTE4) levels did not
correlate with changes (%) in 11-dehydro-thromboxane B2
(11DTXB2) levels in children with bronchial asthma. The per-
centage change was calculated as follows: (level during stable
condition – level during attack) × 100/level during attack.
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pathogenesis of bronchial asthma and the eosinophil
count is correlated with the clinical severity of the dis-
ease.22 However, there are few studies referring to the
correlation between eosinophil count and urinary levels
of LTE4 or 11DTXB2. There was no significant correlation
between urinary levels of LTE4 and the severity of asthma;
however, the severity of the asthma in patients with high
levels of urinary LTE4 tended to be classified as ‘moderate
persistent’ or ‘severe persistent’.
In conclusion, we have shown significantly higher
levels of urinary LTE4 and 11DTXB2 in asthmatic children
during the stable condition. These findings strongly
suggest that the arachidonate cascade metabolites
CysLTs and thromboxanes play certain roles in the patho-
genesis of bronchial asthma in children. According to the
differential changes in urinary levels of these metabolites
during an acute attack, we suppose that an imbalance in
the metabolism arises between the 5-lipoxgenase
pathway and the cyclooxygenase pathway. The measure-
ment of LTE4 and 11DTXB2 in urine samples, which is a
safe and easily available method of estimating the syn-
thesis and release of the mediator in children, would be
useful in understanding the pathogenesis of bronchial
asthma.
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